Molecular mimicry between viral antigens and host proteins can produce cross-reacting antibodies leading to autoimmunity. The coronavirus SARS-CoV-2 causes COVID-19, a disease curiously resulting in varied symptoms and outcomes, ranging from asymptomatic to fatal. Autoimmunity due to cross-reacting antibodies resulting from molecular mimicry between viral antigens and host proteins may provide an explanation. Thus, we computationally investigated molecular mimicry between SARS-CoV-2 Spike and known epitopes. We discovered molecular mimicry hotspots in Spike and highlight two examples with tentative high autoimmune potential and implications for understanding COVID-19 complications. We show that a TQLPP motif in Spike and thrombopoietin shares similar antibody binding properties. Antibodies cross-reacting with thrombopoietin may induce thrombocytopenia, a condition observed in COVID-19 patients. Another motif, ELDKY, is shared in multiple human proteins, such as PRKG1 involved in platelet activation and calcium regulation, and tropomyosin, which is linked to cardiac disease. Antibodies cross-reacting with PRKG1 and tropomyosin may cause known COVID-19 complications such as blood-clotting disorders and cardiac disease, respectively. Our findings illuminate COVID-19 pathogenesis and highlight the importance of considering autoimmune potential when developing therapeutic interventions to reduce adverse reactions.
Accurate cancer subtype prediction is crucial for personalized medicine. Integrating multi-omics data represents a viable approach to comprehending the intricate pathophysiology of complex diseases like cancer. Conventional machine learning techniques are not ideal for analyzing the complex interrelationships among different categories of omics data. Numerous models have been suggested using graph-based learning to uncover veiled representations and network formations unique to distinct types of omics data to heighten predictions regarding cancers and characterize patients’ profiles, amongst other applications aimed at improving disease management in medical research. The existing graph-based state-of-the-art multi-omics integration approaches for cancer subtype prediction, MOGONET, and SUPREME, use a graph convolutional network (GCN), which fails to consider the level of importance of neighboring nodes on a particular node. To address this gap, we hypothesize that paying attention to each neighbor or providing appropriate weights to neighbors based on their importance might improve the cancer subtype prediction. The natural choice to determine the importance of each neighbor of a node in a graph is to explore the graph attention network (GAT). Here, we propose MOGAT, a novel multi-omics integration approach, leveraging GAT models that incorporate graph-based learning with an attention mechanism. MOGAT utilizes a multi-head attention mechanism to extract appropriate information for a specific sample by assigning unique attention coefficients to neighboring samples. Based on our knowledge, our group is the first to explore GAT in multi-omics integration for cancer subtype prediction. To evaluate the performance of MOGAT in predicting cancer subtypes, we explored two sets of breast cancer data from TCGA and METABRIC. Our proposed approach, MOGAT, outperforms MOGONET by 32% to 46% and SUPREME by 2% to 16% in cancer subtype prediction in different scenarios, supporting our hypothesis. Our results also showed that GAT embeddings provide a better prognosis in differentiating the high-risk group from the low-risk group than raw features.
Background: Long non-coding RNA plays a vital role in changing the expression profiles of various target genes that lead to cancer development. Thus, identifying prognostic lncRNAs related to different cancers might help in developing cancer therapy. Method: To discover the critical lncRNAs that can identify the origin of different cancers, we propose the use of the state-of-the-art deep learning algorithm concrete autoencoder (CAE) in an unsupervised setting, which efficiently identifies a subset of the most informative features. However, CAE does not identify reproducible features in different runs due to its stochastic nature. We thus propose a multi-run CAE (mrCAE) to identify a stable set of features to address this issue. The assumption is that a feature appearing in multiple runs carries more meaningful information about the data under consideration. The genome-wide lncRNA expression profiles of 12 different types of cancers, with a total of 4768 samples available in The Cancer Genome Atlas (TCGA), were analyzed to discover the key lncRNAs. The lncRNAs identified by multiple runs of CAE were added to a final list of key lncRNAs that are capable of identifying 12 different cancers. Results: Our results showed that mrCAE performs better in feature selection than single-run CAE, standard autoencoder (AE), and other state-of-the-art feature selection techniques. This study revealed a set of top-ranking 128 lncRNAs that could identify the origin of 12 different cancers with an accuracy of 95%. Survival analysis showed that 76 of 128 lncRNAs have the prognostic capability to differentiate high- and low-risk groups of patients with different cancers. Conclusion: The proposed mrCAE, which selects actual features, outperformed the AE even though it selects the latent or pseudo-features. By selecting actual features instead of pseudo-features, mrCAE can be valuable for precision medicine. The identified prognostic lncRNAs can be further studied to develop therapies for different cancers.
Background Lung cancer is the leading cause of cancer compared to other cancers in the USA despite being the most commonly diagnosed. The overall survival rate of lung cancer is not satisfactory even though having cutting edge treatment methods for cancers. Genomic profiling and biomarker gene identification of lung cancer patients due to genomic alteration may play role in the therapeutics of lung cancer patients. The biomarker genes identified by most of the existing methods (statistical and machine learning based) belong to the whole cohort or population. That is why different people having the same disease get the same kind of treatment which causes different outcomes in terms of success and side effects. So, the identification of biomarker genes for individual patients is very crucial to find efficacious therapeutics. Methods In this study we propose a pipeline to identify lung cancer class-specific and patient-specific key genes which may help to formulate effective therapies for the lung cancer patients. We have used two subtypes of lung cancer-lung adenocarcinoma and lung squamous cell carcinoma to identify subtype-specific (classspecific) and patient-specific key genes using an explainable machine learning approach, SHAP. This approach provides scores to each of the genes for individual patients which tell us the attribution of each feature (gene) for each sample (patients). Result In this study, we applied two variations of SHAP-tree explainer and gradient explainer for which tree-based classifier, XGBoost and deep learning-based classifier, convolutional neural network (CNN) was used as classification algorithms, respectively. The classification accuracy of XGBoost and CNN models 96.3% and 92.6% respectively. Both the SHAP explainers provided attribution scores for each of the genes of individual samples. The class-specific identified top 100 genes were compared with the differentially expressed genes (DEGs) as both of them represent the population-based biomarkers. We also showed that there are minimal number of common genes among the class-specific top-100 genes which validates that the genes are truly class-specific. Similarly, we identified the patient specific top-100 genes based on SHAP score. We found that there are very few genes common among the patients which implicates that the identified patient-specific genes belong to the individual lung cancer patients. Our results also show that there lots of common genes when we identified top-100 genes for the healthy individuals which is due to the less mutation and genomic alteration. Conclusion The proposed approach is capable of identifying key biomarker genes using SHAP. In this study demonstrated the result of SHAP by comparing two different explainers in the context of tree-based and neural network-based classifiers trained on the lung cancer RNA-seq data. We also exhibited that the class-specific SHAP genes are biologically significant by comparing with the output of a statistical approach, DGE analysis. This study also determined patient-specific genes from SHAP scores which may provide many biological insights and aid personalized medicine. The proposed pipeline can be used to determine class-specific and patient-specific biologically relevant genes which can be used to for cancer patients’ diagnosis.
Background: Lung cancer is a leading cause of cancer-related mortality, with disparities in incidence and outcomes observed across different racial and sex groups. Identifying both patient-specific and cohort-specific disparity biomarkers is critical for developing targeted treatments. The lung cancer dataset is highly imbalanced across races, leading to biased results in disparity information if classification is based on race. Method: This study developed an explainable artificial intelligence-based framework, TILDA-X, which designs classification models based on disease conditions instead of races to mitigate racial imbalance in the dataset and applies explainable AI to delineate patient-specific disparity information. A lung cancer transcriptome dataset with three disease conditions—lung adenocarcinoma, lung squamous cell carcinoma, and healthy samples—was used to develop classification models. Applying a bottom-up approach from patient-specific disparity information, the cohort-specific disparity information is discovered for different racial and sex groups, African American males, European American males, African American females, and European American females. Results: Classification based on disease conditions achieved accuracy between 88% and 100% for minority groups (African American males and females), whereas it was only between 0% and 16% for race-based classification, which underscores the significance of the proposed approach. Functional analysis of sub-cohort-specific biomarker genes revealed unique pathways associated with lung cancers in different races and sexes. Among the significant pathways identified, over ~63% overlapped with previously reported lung cancer-related studies, supporting the biological validity of our findings. Overall, combining disease conditions-based classification with explainable AI, this study provides a robust, interpretable framework for characterizing race- and sex-specific disparities in lung cancer, offering a foundation for precision oncology and equitable therapeutic development based on transcriptome profile only.
Motivation: Convolutional neural networks (CNNs) offer potential for analyzing non-grid structured data, such as biological array data, by converting it into image-like formats using principal component analysis (PCA) of pathway genes. However, PCA-derived principal components (PCs) from the entire dataset capture global variance but fail to extract sub-cohort (class-specific) variances. Consequently, CNNs trained on global PCs perform poorly in survival prediction of glioblastoma multiforme (GBM), and the corresponding explanation of CNN outcomes may not align with disease-relevant pathways. Results: We present PathX-CNN, an explainable CNN framework that addresses these limitations by integrating multi-omics data through pathway-based images derived from sub-cohort-specific PCs. PathX-CNN outperformed existing pathway-based methods in predicting long-term survival (LTS) versus non-LTS in GBM. By leveraging SHAP (SHapley Additive exPlanations), a cooperative game theory-based explainable AI method, PathX-CNN identified biologically plausible pathways associated with GBM survival. Additionally, experiments on other cancer types demonstrated superior performance compared to traditional approaches. PathX-CNN demonstrates the potential of CNNs for multiomics integration, offering both improved prediction accuracy and pathway-specific insights into disease mechanisms. Code Availability: https://github.com/codebysobhan/PathX-CNN Contact: amondal@fiu.edu Supplementary information: Supplementary data are available at Bioinformatics online.